Showing results (1-10 of 63) with videos related to
Sort By:
Pageof 7
The Biochemical Journal|January 9, 2007
Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCATKyriakos E Kypreos, Vassilis I ZannisJournal of Lipid Research|December 13, 2005
LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in miceKyriakos E Kypreos, Vassilis I ZannisJournal of Molecular Medicine (Berlin, Germany)|February 28, 2006
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDLVassilis I Zannis, Angeliki Chroni, Monty KriegerJournal of Biomedical Research|November 8, 2017
Role of apolipoproteins, ABCA1 and LCAT in the biogenesis of normal and aberrant high density lipoproteinsVassilis I Zannis, Shi Su, Panagiotis FotakisThe Journal of Biological Chemistry|July 28, 2010
Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptorsIoanna Mosialou, Vassilis I Zannis, Dimitris KardassisPlos One|July 5, 2013
Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol EffluxGeorgios Daniil, Vassilis I Zannis, Angeliki ChroniBiochemistry|September 25, 2007
Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoidsEfstathia Thymiakou, Vassilis I Zannis, Dimitris KardassisThe Biochemical Journal|June 15, 2006
Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathwayVarvara Nikolaidou-Neokosmidou, Vassilis I Zannis, Dimitris KardassisJournal of Lipid Research|September 24, 2010
Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4Alexander M Vezeridis, Konstantinos Drosatos, Vassilis I ZannisBiochemical Pharmacology|September 19, 2012
Pharmacodynamic and pharmacokinetic analysis of apoE4 [L261A, W264A, F265A, L268A, V269A], a recombinant apolipoprotein E variant with improved biological propertiesAngeliki Lampropoulou, Vassilis I Zannis, Kyriakos E KypreosPageof 7